Clinical Trials Registration
infection, coronavirus disease 2019 convalescent, acute coronavirus disease 2019
VIRUS, INFECTION, MAY, CORONAVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME
NCT04373460.Early treatment with coronavirus disease 2019 convalescent plasma was not associated with faster symptom resolution than control treatment, in contrast with decreased hospitalization in the same population, suggesting that the timing antibody treatment may affect hospitalization and symptom progression differently.With the introduction of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in early 2020, clinicians encountered atypical symptom profiles [Previous studies have shown variability in the time to resolution of symptoms after acute coronavirus disease 2019 (COVID-19) infection [From January to May 2020, a study of approximately 3000 confirmed COVID-19 cases reported 60% of participants with improvement at 20 days, 80% at 30 days, and 91% at 60 days [We investigated the influence of COVID-19 convalescent plasma (CCP) versus control plasma on resolution of symptoms from the day of transfusion through day 14 of follow-up as part of a randomized controlled trial [